Evaluation of the effectiveness of platinum-based chemotherapy in ovarian cancer patients carriers of mutations in BRCA1/2
Vol. 60 No. 3 (2014), Articles
Vol. 60 No. 3 (2014)

Evaluation of the effectiveness of platinum-based chemotherapy in ovarian cancer patients carriers of mutations in BRCA1/2

Articles
https://doi.org/10.37469/0507-3758-2014-60-3-339-342
Published 15.12.2014
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
##article.numberofdownloads## 76
##article.numberofviews## 250
PDF (Русский)

Keywords

BRCA-mutation carriers
platinum-sensitive ovarian cancer
hereditary mutations in BRCA

How to Cite

, , , & . (2014). Evaluation of the effectiveness of platinum-based chemotherapy in ovarian cancer patients carriers of mutations in BRCA1/2. Voprosy Onkologii, 60(3), 339–342. https://doi.org/10.37469/0507-3758-2014-60-3-339-342
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

The purpose of this study was to examine the clinical significance of mutations in BRCA1/2 in the formation of response to neoadjuvant platinum-based chemotherapy for ovarian cancer (OC). All patients who had had neoadjuvant chemotherapy (NCT) in our Institute from January 2000 till January 2013 were tested for carrier of mutations in BRCA1/2. In accordance with the BRCA-status we formed two groups - a group with hereditary advanced OC and a group with non-hereditary advanced OC. In the formed groups there was studied the effectiveness of chemotherapy. Patients carriers of mutations in BRCA1/2 showed a complete clinical response in 34 % of cases, compared to 4 % in the non-hereditary OC. Analysis of the results of cytoreductive surgery showed that in the group of hereditary cancer it was significantly higher the percentage of performing optimal cytoreductive operations (71 % vs 48 %). We analyzed the cases of complete pathologic response in all patients NCT and found that full pathomorphosis significantly associated with BRCA-status and the type of ongoing chemotherapy. It was important to note that all carriers of mutations in BRCA1/2 responded to cisplatin chemotherapy.
https://doi.org/10.37469/0507-3758-2014-60-3-339-342
##article.numberofdownloads## 76
##article.numberofviews## 250
PDF (Русский)

References

Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Неоадъювантное и адъювантное лечение рака молочной железы // МИА. - 2008.

Соколенко А.П., Иевлева А.Г., Митюшкина Н.В., и др. - Синдром наследственного рака молочной железы и яичников в Российской Федерации // Acta natura. - 2010. - Т. 2. - № 4. - С. 35-39.

Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer // JAMA. - 2000. - Vol. 3. - P. 2260-2265.

Cass I., Baldwin R.L., Varkey T., et al. - Improved survival in women with BRCA-associated ovarian carcinoma // Cancer. - 2003. - Vol. 97. - P. 2187-2195.

Sassen S., Schmalfeldt B., Avril N. et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer // Hum Pathol. - 2007. - Vol. 38. - P. 7-8.

Suspitsin E.N., Sherina N.Y., Ponomariova D.N. et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients // Hered. Cancer Clin. Pract. - 2009. - Vol. 10. - P. 86-97.

Tutt A., Ashworth A. - The relationship between the roles of BRCA genes in DNA repair and cancer predisposition // Trends Mol Med. - 2002. - Vol. 8. - P. 571-576.

Tan D.S., Rothermundt C., Thomas K., et al. - “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 // J Clin Oncol. - 2008. - Vol. 26. - P. 5530-5536.

Yoshida K., Miki Y., Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage // Cancer Sci. - 2004. - Vol. 95. - P. 866-871.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...